PubRank

S Jurriaans

Author PubWeight™ 45.68‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J Virol Methods 1994 3.13
2 Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000 2.14
3 Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999 2.09
4 High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function. Eur J Immunol 2001 1.99
5 Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998 1.88
6 OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol 2001 1.75
7 Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2000 1.68
8 Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 1995 1.65
9 Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS 1999 1.64
10 Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression. J Virol 1999 1.63
11 Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection. AIDS 2000 1.47
12 Qualitative and quantitative detection of HIV-1 RNA by nucleic acid sequence-based amplification. AIDS 1993 1.44
13 [Primary HIV-infection: infectious mononucleosis-like presentation with treatment options]. Ned Tijdschr Geneeskd 1999 1.39
14 Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999 1.32
15 Evaluation of the World Health Organization staging system for HIV infection and disease in Ethiopia: association between clinical stages and laboratory markers. AIDS 1999 1.31
16 Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000 1.26
17 Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998 1.21
18 Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group. AIDS 1998 1.20
19 Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine. AIDS 2000 1.16
20 The one-tube quantitative HIV-1 RNA NASBA: precision, accuracy, and application. PCR Methods Appl 1995 1.13
21 Inhibition of HIV-1 infectivity by phosphate-methylated DNA: retraction. Science 1990 1.00
22 Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 1995 0.99
23 Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1. Clin Infect Dis 2001 0.99
24 The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998 0.96
25 The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group. AIDS 2000 0.87
26 Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations. AIDS Res Hum Retroviruses 2000 0.86
27 Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection. Clin Infect Dis 2001 0.85
28 In vivo delayed-type hypersensitivity skin test anergy in human immunodeficiency virus type 1 infection is associated with T cell nonresponsiveness in vitro. J Infect Dis 1998 0.85
29 Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine. J Neuroimmunol 2000 0.82
30 Retracted Phosphate-methylated DNA aimed at HIV-1 RNA loops and integrated DNA inhibits viral infectivity. Science 1990 0.82
31 [Intra uterine insemination with processed sperm for HIV serodiscordant couples in whom the man is HIV positive]. Ned Tijdschr Geneeskd 2005 0.80
32 The ADAM study continued: maintenance therapy after 50 weeks of induction therapy. AIDS 2001 0.79
33 Reproduction and fertility in human immunodeficiency virus type-1 infection. Hum Reprod Update 2006 0.79
34 Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial. Antivir Ther 2001 0.77
35 Human liver L-alanine-glyoxylate aminotransferase: characteristics and activity in controls and hyperoxaluria type I patients using a simple spectrophotometric method. Clin Chim Acta 1990 0.77
36 An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. AIDS 1998 0.76
37 [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]. Ned Tijdschr Geneeskd 2001 0.75
38 [Zidovudine-resistant HIV strains in untreated intravenous drug users and homosexual men in Amsterdam infected in 1996]. Ned Tijdschr Geneeskd 1997 0.75
39 Diversity in residual alanine glyoxylate aminotransferase activity in hyperoxaluria type I: correlation with pyridoxine responsiveness. J Inherit Metab Dis 1988 0.75
40 Semen parameters of a semen donor before and after infection with human immunodeficiency virus type 1: case report. Hum Reprod 2004 0.75
41 [Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results]. Ned Tijdschr Geneeskd 1998 0.75